|1.||Choi, Jong-Moon: 1 article (04/2006)|
|2.||Jin, Hyo-Eon: 1 article (04/2006)|
|3.||Hong, Soon-Sun: 1 article (04/2006)|
|4.||Shim, Chang-Koo: 1 article (04/2006)|
|5.||Hong, S S: 1 article (07/2000)|
|6.||Chung, S J: 1 article (07/2000)|
|7.||Shim, C K: 1 article (07/2000)|
04/01/2006 - "In addition, the in vivo hepatic uptake clearance of TBuMA from the plasma to the liver was decreased by 50% in cholestasis. "
04/01/2006 - "When [3H]TBuMA was intravenously administered1 the AUC value for TBuMA was significantly increased by 79% in cholestasis, and its total systemic clearance was consequently decreased by 46%. "
04/01/2006 - "Altered pharmacokinetics and hepatic uptake of TBuMA in ethynylestradiol-induced cholestasis."
04/01/2006 - "Therefore, we conclude that the inhibition of the hepatic uptake process by the cholestasis may be in part due to the increased formation of ion-pair complexes of TBuMA with bile salts in the plasma."
04/01/2006 - "Since TBuMA forms ion-pair complexes with anionic components such as bile salts, the decreased hepatic uptake of TBuMA in cholestasis may be due to a change in endogenous components, e.g., bile salts in the plasma. "
|3.||Bile Acids and Salts (Bile Acids)